X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The project is the first step in determining if there is a basis for a further collaboration between Mymetics and PCI Biotech, of short duration and without immediate commercial impact for either of the parties involved.
Lead Product(s): Nucleic Acid Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Mymetics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 31, 2022
Details:
PCI of gemcitabine with Amphinex shows an innovative treatment that could potentially produce significant local tumour response in patients. The study is well designed to demonstrate the potential benefit of Amphinex induced PCI of gemcitabine in bile duct cancer patients.
Lead Product(s): Fimaporfin,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Amphinex
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2022
Details:
This collaboration is an additional mark of interest from a cutting-edge biotech company developing therapies with emerging advanced technologies, with a large potential in future medicine
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: MDimune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 05, 2022
Details:
The interaction with the FDA and EMA initiated to explore the opportunity for a modified study design to address the retention risk in the control arm of the RELEASE study of Amphinex (Fimaporfin).
Lead Product(s): Fimaporfin,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Amphinex
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2021
Details:
The fimaChem treatment regimen consists of an intravenous injection of fimaporfin, a photosensitiser drug followed four days later by an intravenous infusion of gemcitabine and a laser light application in the bile duct.
Lead Product(s): Fimaporfin,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Amphinex
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2021
Details:
First US patient has been enrolled into the fimaChem pivotal RELEASE study with registration intent in inoperable bile duct cancer patients.
Lead Product(s): Fimaporfin,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Amphinex
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2021
Details:
The European patent covers the intended use of fimaChem in combination with gemcitabine for the treatment of cholangiocarcinoma (bile duct cancer).
Lead Product(s): Fimaporfin,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: Amphinex
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Company's decision not to enter into a definitive agreement is primarily based on a strategic evaluation of current development needs. Results have continued to be achieved with the fimaNAc platform in the collaboration.
Lead Product(s): Nucleic acid therapeutics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 21, 2020
Details:
PCI Biotech has announced case report series from the Phase I study with PCI Biotech's proprietary drug fimaporfin (AmphinexTM), for the treatment of inoperable extrahepatic bile duct cancer (eCCA), is accepted for publishing in Endoscopy International Open.
Lead Product(s): Fimaporfin,Gemcitabine
Therapeutic Area: Oncology Product Name: Amphinex
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
